ZK245186

Bayer · Phase 2 active Small molecule

At a glance

Generic name	ZK245186
Also known as	Mapracorat (BAY86-5319)
Sponsor	Bayer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis (PHASE2)
1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat (PHASE1)
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ZK245186 CI brief — competitive landscape report
ZK245186 updates RSS · CI watch RSS
Bayer portfolio CI